Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbapenems

S R Norrby1

  • 1Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin.

The Medical Clinics of North America
|July 1, 1995
PubMed
Summary

Carbapenems are potent antibiotics effective against most bacteria. Meropenem offers advantages over imipenem-cilastatin, particularly in treating bacterial meningitis with fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2004
Same author

S Ragnar Norrby--Director General of the Swedish Institute for Infectious Disease Control. Interview by Pam Das.

The Lancet. Infectious diseases·2002
Same author

Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis.

Scandinavian journal of infectious diseases·2002
Same author

Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.

Chemotherapy·2001
Same author

Levofloxacin.

Expert opinion on pharmacotherapy·2001
Same author

Urinary tract infections: disease panorama and challenges.

The Journal of infectious diseases·2001

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Carbapenems are broad-spectrum beta-lactam antibiotics crucial for treating bacterial infections.
  • Key exceptions to carbapenem coverage include X. maltophilia, E. faecium, and resistant strains of staphylococci and pneumococci.
  • Emergence of resistance, primarily in P. aeruginosa, is a concern with carbapenem use.

Purpose of the Study:

  • To review the clinical utility and comparative aspects of carbapenem antibiotics.
  • To highlight the pharmacokinetic differences and safety profiles of imipenem-cilastatin and meropenem.
  • To provide guidance on the appropriate use of carbapenems in treating serious infections.

Main Methods:

  • Literature review of carbapenem antibiotics, focusing on imipenem-cilastatin and meropenem.
  • Analysis of pharmacokinetic properties, resistance patterns, and safety data.
  • Evaluation of clinical indications and dosing recommendations.

Main Results:

  • Carbapenems exhibit broad-spectrum activity, with limited exceptions.
  • Imipenem's renal metabolism necessitates co-administration with cilastatin, unlike meropenem.
  • Meropenem demonstrates a favorable safety profile, especially regarding neurological side effects and suitability for bacterial meningitis treatment.
  • Carbapenems are primarily recommended as empiric monotherapy for severe infections.

Conclusions:

  • Carbapenems remain vital antibiotics for serious bacterial infections.
  • Meropenem presents advantages over imipenem-cilastatin due to its pharmacokinetic profile and safety, particularly for meningitis.
  • Judicious use of carbapenems, primarily as monotherapy, is recommended to preserve their efficacy and minimize resistance.

Related Experiment Videos